The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The way to do it is set up a stocks and shares account, then transfer max £20k before 5th April 2023-2024 via a phone call to your trading house, request Bed and ISA transfer. You can then do the same 1 week later which will use your allowance for 2024-2025.
The process is simple, you will have to sell and buy back in, this takes a couple of minutes so minimal loss, any future gains are then tax free under your stock and share wrapper that you now have. Do the same in your Mrs name and have max benefit on future gains.
The way to do it is set up a stocks and shares account, then transfer max £20k before 5th April 2023-2024 via a phone call to your trading house, request Bed and ISA transfer. You can then do the same 1 week later which will use your allowance for 2024-2025.
The process is simple, you will have to sell and buy back in, this takes a couple of minutes so minimal loss, any future gains are then tax free under your stock and share wrapper that you now have. Do the same in your Mrs name and have max benefit on future gains.
Suggest you do more research before writing rubbish, you clearly don’t understand the business now or in the future direction it is taking, forget the past as it is irrelevant.
Available of RR website should you want to do some real research
1, Strategic update and mid-term targets
2, Financial summary and capital frame
3, Civil Aerospace
4, Defence
5, Power Systems
6, Key takeaways
Must be soon, I watched Tufan say this during presentation to JM Morgan and others during the week, he was very confident on winning the government over. He also mentioned having a broad set of partners on board to strengthen the position and deliver the overall solution as well as reduce the future capital call which is very important as this thing will be very expensive.
AbbVie signs $10 bln deal to buy cancer drugmaker ImmunoGen
https://www.reuters.com/markets/deals/abbvie-buy-immunogen-101-billion-boost-cancer-drug-portfolio-2023-11-30/
Watched it all, as I said this morning good management team with a clear strategy, the CFO impressed me, she knows what to do to get results, it was great RNS this morning which the market also enjoyed, decent rise today, onwards to £3.10
Cathay Pacific Airways Ltd (0293.HK) is leaning towards placing an order for around six Airbus (AIR.PA) A350 freighters as the Hong Kong carrier renews the oldest section of its fleet of dedicated 747 cargo jets, industry sources said.
https://www.reuters.com/markets/deals/cathay-seen-favouring-airbus-widely-watched-freighter-deal-2023-11-27/
We are progressing well, we need to be realistic, from where it was less then 2 years ago to where RR is now, we should be grateful, very strong senior management team with a clear strategy which seemed to be missing over the past years. 2024 big one
Could this be good news for Hemo?
https://www.england.nhs.uk/2021/07/nhs-england-announces-new-innovative-medicines-fund-to-fast-track-promising-new-drugs/
Long-haul carrier Emirates orders 15 Airbus A350 after engine dispute during Dubai Air Show
DUBAI, United Arab Emirates (AP) — Long-haul carrier Emirates said Thursday it will purchase 15 additional Airbus A350-900s worth $6 billion after a spat between the airline and the European manufacturer went unusually public during this week's Dubai Air Show.
Looking on companies house, SKYGEM have only 2 people registered as Directors running the company
Director 1, SHEN. Zheqing (investment banker)sole shareholder of ZQ Capital investments.
Zheqing Shen serves as Independent Director of the Company. Mr. Shen is the founding member of ZQ Capital Limited, a boutique investment and advisory firm. Prior to founding ZQ Capital in 2015, Mr. Shen was managing director and head of the China Financial Institutions Business at Barclays from 2011 to 2015. From 2004 to 2010, he worked with Goldman Sachs as an investment banker in its New York and Hong Kong offices. In addition to his service on our Board, Mr. Shen has also served since 2016 on the board of directors and the Audit, Remuneration and Nomination Committees of KFM Kingdom Holdings Limited, a precision metals engineering and manufacturing company that is listed on the Hong Kong Stock Exchange. Mr. Shen has a B.A. in mathematics and economics from Wesleyan University.
Director 2, YUAN Kai is also a director of another major company